Panobinostat | LBH589;NVP-LBH589 | HDAC | AmBeed-信号通路专用抑制剂

首页 / / / 组蛋白去乙酰化酶 / Panobinostat

帕比司他 /Panobinostat {[allProObj[0].p_purity_real_show]}

货号：A165763 同义名： LBH589;NVP-LBH589

Panobinostat (LBH589; NVP-LBH589) 是一种强效且口服活性的非选择性HDAC抑制剂，具有抗肿瘤活性。在低浓度（8-31 nM）下诱导HIV-1病毒的产生，并在潜伏感染的细胞中刺激HIV-1的表达。Panobinostat还诱导细胞凋亡和自噬，可用于研究难治性或复发性多发性骨髓瘤。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Panobinostat 化学结构
CAS号：404950-80-7

Panobinostat 3D分子结构
CAS号：404950-80-7

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Panobinostat 纯度/质量文件产品仅供科研

货号：A165763 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell, 2024, 101755. Ambeed. [ A399663 ]; • EMBO J., 2024. Ambeed. [ A295334 ]; • JMC, 2024, 67(20): 18265-18289. Ambeed. [ A538667 , A341145 , A117430 , A172297 ]; • JMC, 2024. Ambeed. [ A210558 , A1518164 ]; • Cell Death Discov., 2024, 10, 436. Ambeed. [ A384235 ]; 更多 >

组蛋白去乙酰化酶亚型比较

产品名称	HD1 ↓ ↑	HD2 ↓ ↑	HDAC ↓ ↑	HDAC1 ↓ ↑	HDAC10 ↓ ↑	HDAC11 ↓ ↑	HDAC2 ↓ ↑	HDAC3 ↓ ↑	HDAC4 ↓ ↑	HDAC5 ↓ ↑	HDAC6 ↓ ↑	HDAC7 ↓ ↑	HDAC8 ↓ ↑	HDAC9 ↓ ↑	其他靶点	纯度
Givinostat HCl monohydrate	++++ HD1-A, IC50: 16 nM HD1-B, IC50: 7.5 nM	+++ HD2, IC50: 10 nM														99%+
MC1568	++ HD1-A (Maize), IC50: 100 nM HD1-B (Maize), IC50: 3.4 μM															96%
Trichostatin A			++++ HDAC, IC50: ~1.8 nM													99%+
Scriptaid			✔													99%+
Valproic acid sodium			✔												Autophagy	97%
AR-42			+++ HDAC, IC50: 30 nM													99%+
Dacinostat			+++ HDAC, IC50: 32 nM													98+%
CUDC-101			++++ HDAC, IC50: 4.4 nM	++++ HDAC1, IC50: 4.5 nM	+++ HDAC10, IC50: 26.1 nM		+++ HDAC2, IC50: 12.6 nM	++++ HDAC3, IC50: 9.1 nM	+++ HDAC4, IC50: 13.2 nM	+++ HDAC5, IC50: 11.4 nM	++++ HDAC6, IC50: 5.1 nM	+ HDAC7, IC50: 373 nM	++ HDAC8, IC50: 79.8 nM	++ HDAC9, IC50: 67.2 nM	HER2,EGFR	99%+
M344			++ HDAC, IC50: 100 nM													99%+
Splitomicin			+ Sir2p, IC50: 60 μM													95%
Panobinostat			++++ HDAC (MOLT-4 cells), IC50: 5 nM HDAC (Reh cells), IC50: 20 nM													98%
Sodium 4-Phenylbutyrate			✔													98%
Vorinostat			+++ HDAC, IC50: ~10 nM													98%
Curcumin			✔												NF-κB,Nrf2	98%
Belinostat			+++ HDAC, IC50: 27 nM													98%
RG-2833				++ HDAC1, Ki: 32 nM				++ HDAC3, Ki: 5 nM								98%
Valproic acid				+ HDAC1, IC50: 0.4 mM												98%
BG45				+ HDAC1, IC50: 2 μM			+ HDAC2, IC50: 2.2 μM	+ HDAC3, IC50: 289 nM								99%+
Entinostat				+ HDAC1, IC50: 0.51 μM				+ HDAC3, IC50: 1.7 μM								98%
Resminostat				+++ HDAC1, IC50: 42.5 nM				++ HDAC3, IC50: 50.1 nM			++ HDAC6, IC50: 71.8 nM					98+%
Romidepsin				+++ HDAC1, IC50: 36 nM			+++ HDAC2, IC50: 47 nM									99%+
Parthenolide				✔											NF-κB,p53	97% HPLC
Tacedinaline				+ HDAC1, IC50: 0.9 μM			+ HDAC2, IC50: 0.9 μM	+ HDAC3, IC50: 1.2 μM								98%
Mocetinostat				++ HDAC1, IC50: 0.15 μM		+ HDAC11, IC50: 0.59 μM	+ HDAC2, IC50: 0.29 μM	+ HDAC3, IC50: 1.66 μM								98%
WT-161				++++ HDAC1, IC50: 8.35 nM			+++ HDAC2, IC50: 15.4 nM				++++ HDAC6, IC50: 0.4 nM					99%+
Fimepinostat				++++ HDAC1, IC50: 1.7 nM	++++ HDAC10, IC50: 2.8 nM	++++ HDAC11, IC50: 5.4 nM	++++ HDAC2, IC50: 5.0 nM	++++ HDAC3, IC50: 1.8 nM			+++ HDAC6, IC50: 27 nM					99%+
Tucidinostat				++ HDAC1, IC50: 95 nM	++ HDAC10, IC50: 78 nM		++ HDAC2, IC50: 160 nM	++ HDAC3, IC50: 67 nM								99%+
Santacruzamate A							++++ HDAC2, IC50: 119 pM									99%+
(E,E)-RGFP966								++ HDAC3, IC50: 80 nM								99%+
LMK-235									+++ HDAC4, IC50: 11.9 nM	++++ HDAC5, IC50: 4.2 nM						99%+
Tasquinimod									✔							99%+
CAY10603											++++ HDAC6, IC50: 2 pM					98%
Tubastatin A											+++ HDAC6, IC50: 15 nM					98%
Tubacin											++++ HDAC6, IC50: 4 nM					99%+
ACY-738											++++ HDAC6, IC50: 1.7 nM					99%+
Nexturastat A											++++ HDAC6, IC50: 5 nM					99%+
BRD73954											+++ HDAC6, IC50: 36 nM		++ HDAC8, IC50: 120 nM			98%
Tubastatin A HCl											+++ HDAC6, IC50: 15 nM		+ HDAC8, IC50: 854 nM			98%
PCI-34051													+++ HDAC8, IC50: 10 nM			99%+
Ricolinostat				++ HDAC1, IC50: 58 nM			++ HDAC2, IC50: 48 nM	++ HDAC3, IC50: 51 nM			++++ HDAC6, IC50: 4.7 nM		++ HDAC8, IC50: 100 nM			99%+
Droxinostat								+ HDAC3, IC50: 16.9 μM			+ HDAC6, IC50: 2.47 μM		+ HDAC8, IC50: 1.46 μM			99%+
Abexinostat				++++ HDAC1, Ki: 7 nM	+++ HDAC10, IC50: 24 nM		+++ HDAC2, Ki: 19 nM	++++ HDAC3/SMRT, Ki: 8.2 nM			+++ HDAC6, Ki: 17 nM		+ HDAC8, IC50: 280 nM			98%+
Citarinostat				+++ HDAC1, IC50: 35 nM			+++ HDAC2, IC50: 45 nM	+++ HDAC3, IC50: 46 nM			++++ HDAC6, IC50: 2.6 nM		++ HDAC8, IC50: 137 nM			99%+
HPOB				+ HDAC1, IC50: 2.9 μM	+ HDAC10, IC50: 3.0 μM		+ HDAC2, IC50: 4.4 μM	+ HDAC3, IC50: 1.7 μM			++ HDAC6, IC50: 56 nM		+ HDAC8, IC50: 2.8 μM			97%
Quisinostat 2HCl				++++ HDAC1, IC50: 0.11 nM	++++ HDAC10, IC50: 0.46 nM	++++ HDAC11, IC50: 0.37 nM	++++ HDAC2, IC50: 0.33 nM	++++ HDAC3, IC50: 4.86 nM	++++ HDAC4, IC50: 0.64 nM	++++ HDAC5, IC50: 3.69 nM			++++ HDAC8, IC50: 4.26 nM			99+%
Domatinostat				+ HDAC1, IC50: 1.20 μM	+ HDAC10, IC50: 21 μM	+ HDAC11, IC50: 9.7 μM	+ HDAC2, IC50: 1.12 μM	+ HDAC3, IC50: 0.57 μM		+ HDAC5, IC50: 11.3 μM				+ HDAC9, IC50: 50 μM		99%+
TMP269									++ HDAC4, IC50: 157 nM	++ HDAC5, IC50: 97 nM		+++ HDAC7, IC50: 43 nM		+++ HDAC9, IC50: 23 nM		99%+
Pracinostat				++ HDAC1, IC50: 49 nM	+++ HDAC10, IC50: 40 nM	++ HDAC11, IC50: 93 nM	++ HDAC2, IC50: 96 nM	+++ HDAC3, IC50: 43 nM	++ HDAC4, IC50: 56 nM	+++ HDAC5, IC50: 47 nM	+ HDAC6, IC50: 1.008 μM	++ HDAC7, IC50: 137 nM	++ HDAC8, IC50: 140 nM	++ HDAC9, IC50: 70 nM		99%+
TMP195									++ HDAC4, Ki: 59 nM	++ HDAC5, Ki: 60 nM		+++ HDAC7, Ki: 26 nM		+++ HDAC9, Ki: 15 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Panobinostat 生物活性

靶点	HDAC HDAC (MOLT-4 cells), IC50:5 nM HDAC (Reh cells), IC50:20 nM
描述	HDACs (Histone deacetylases) are a group of enzymes that remove acetyl groups and regulate the histone tail, protein-DNA interaction, chromatin conformation, and even transcription. There are 18 mammalian HDACs divided into four classes: class I (HDACs 1, 2, 3, 8), class II (HDACs 4, 5, 6, 7, 9, 10), class III (sirtuin family: sirt1-sirt7) and class IV (HDAC 11)^[1]. Panobinostat, also called as LBH-589 or NVP-LBH589, is broad-spectrum HDAC inhibitor with hydroxamate-based structure (IC50 value measured by cell-free assay not tested). A maximum effect of 85% apoptosis with 20 nM panobinostat in MOLT-4 cells and 80% apoptosis with 50 nM panobinostat in Reh cells can observed at 72h. Panobinostat can inhibit proliferation and cell-cycle progression in the two ALL cells. IC50 of panobinostat in anti-proliferation of MOLT-4 cells is approximately 5 nM and for Reh cells is approximately 20 nM. Compared with the control cells, panobinostat treatment for 24h (up to 50 nM) caused a 2- to 3-fold increase in the number of cells in the G2/M phase. Like other HDAC pan inhibitors, the hyperacetylation of H3K9 and H4K8, which are the biomarkers for the inhibition of class 1 HDACs, can be observed in MOLT-4 cells treated with panobinostat (10 - 50 nM) for 24h in a dose-dependent manner. Accompanied by that, the induction of p21 and p27 expression, as well as a decrease of c-Myc expression can also be found in the same time with 10 - 20 nM panobinostat. Echoing to the cell-arrest and growth inhibition, the apoptosis and DNA damage response genes, like GADD45A, GADD45B, GADD45G, FANCG, and FOXO3A can be increased robustly in the ALL cells after treatment with 50 nM panobinostat for 24h. These suggest that the growth inhibition effect of panobinostat may due to the apoptosis and DNA damage response caused by HDACs inhibition^[2]. Panobinostat in combination with bortezomiband dexamethasone is approved by FDA for the treatment for patients with multiple myeloma who receive prior treatment with bortezomib and an immunomodulatory (IMiD) agent^[3].
作用机制	Panobinostat has hydroxamate-based structure, which can chelate the Zn2+ ion of HDACs^[2].

Panobinostat 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
769-P	10/25/50 nM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner synergistically with ritonavir	25279191
769-P	50 nM	Apoptosis Assay	48 h	induces cell apoptosis combined ritonavir	25279191
769-P	25/50 nM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner synergistically with bortezomib	25176354
769-P	50 nM	Colony Formation Assay	7-14 d	suppressed colony formation significantly combined with with bortezomib	25176354

Panobinostat 动物研究

Dose

Mice^[4] (i.p.): 5 mg/kg- 20 mg/kg

Administration

i.p.

Pharmacokinetics

Animal	Rats^[5]	Dogs^[5]
Dose	10 mg/kg	0.5 mg/kg
Administration	i.v.
C_max	1016 ng/ml	76.7 ng/ml
T_1/2	3.81 ± 1.39 h	16 h
AUC_0→∞		155 ng·h/ml
CL	22.1 ± 3.49 L/h/kg	3.3 L/h/kg
T_max	0.083 h
Vss	40.2 ± 16 L/kg	42 L/kg
AUC_inf	459 ± 70 ng·h/ml

Panobinostat 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02506959	Plasma Cell Leukemia ... 展开 >> Plasmacytoma Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma 收起 <<	Phase 2	Recruiting	September 14, 2019	United States, Texas ... 展开 >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Yago L. Nieto 713-792-8750 ynieto@mdanderson.org Principal Investigator: Yago L. Nieto 收起 <<
NCT00449761	Leukemia, Myeloid, Chronic	Phase 2 Phase 3	Completed	-	-
NCT01055483	Acute Myeloid Leukemia	Phase 1	Completed	-	France ... 展开 >> Novartis Investigative Site Paris Cedex 4, France, 75181 Novartis Investigative Site Paris, France, 75475 Germany Novartis Investigative Site Dresden, Germany, 01307 Novartis Investigative Site Frankfurt, Germany, 60590 Novartis Investigative Site Hannover, Germany, 30625 Novartis Investigative Site Ulm, Germany, 89081 收起 <<

Panobinostat 参考文献

[1]Yoon S, Eom GH, et al. HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases. Chonnam Med J. 2016 Jan;52(1):1-11.

[2]Scuto A, Kirschbaum M, et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood. 2008 May 15;111(10):5093-100.

[3]Raedler LA, et al. Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma. Am Health Drug Benefits. 2016 Mar;9(Spec Feature):84-7.

[4]Ocio EM, Vilanova D, et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica. 2010 May;95(5):794-803.

[5]205353Orig1s000PharmR

Panobinostat 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.86mL

0.57mL

0.29mL

14.31mL

2.86mL

1.43mL

28.62mL

5.72mL

2.86mL

Panobinostat 技术信息

CAS号	404950-80-7
分子式	C₂₁H₂₃N₃O₂
分子量	349.43

别名	LBH589;NVP-LBH589
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

溶解度

DMSO: 105 mg/mL(300.49 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

IP 2% DMSO+2% Tween80+30% PEG300+water 9 mg/mL clear

PO 0.5% CMC-Na 50 mg/mL suspension

大规格询价

* 公司或机构名称：

* 姓名：

* 电话：

* 邮箱： * 国家/区域： * 需求量：

* 货号：

* CAS号：

* 产品名称：在线留言：

请填写此表格索取QC报告。我们很快就会发送到您的邮箱。您的信息在我们这里是安全的。*是必填项.

产品名称： * 货号：

* 姓名：

* 电话：

* 邮箱： * 公司或机构名称： * 部门：留言给我们：

摩尔计算器

计算溶液所需的质量，体积或浓度。 Ambeed 摩尔浓度计算器基于以下方程式：

浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)=质量 (g)

浓度

体积

分子量

质量

*在制备母液时，请始终参考产品标签或 MSDS / COA（在产品页面可下载）上所显示的对应批次产品的分子量。

靶点

靶点	数值

HDAC	HDAC (MOLT-4 cells), IC50:5 nM HDAC (Reh cells), IC50:20 nM

总药量计算器

动物实验：给药剂量 mg/kg 动物体重 g 动物数量只每天给药次给药天

需要的总药量： mg

工作液计算器

动物实验：给药剂量 mg/kg 动物体重 g 给药体积 μL

您需要配制的工作液浓度为：mg/mL

细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源

769-P	10/25/50 nM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner synergistically with ritonavir	25279191
769-P	50 nM	Apoptosis Assay	48 h	induces cell apoptosis combined ritonavir	25279191
769-P	25/50 nM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner synergistically with bortezomib	25176354
769-P	50 nM	Colony Formation Assay	7-14 d	suppressed colony formation significantly combined with with bortezomib	25176354
769-P	50 nM	Apoptosis Assay	48 h	induces cell apoptosis	25176354
786-O	10/25/50 nM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner synergistically with ritonavir	25279191
786-O	50 nM	Apoptosis Assay	48 h	induces cell apoptosis combined ritonavir	25279191
A549	10/15/20 nM	Growth Inhibition Assay	72 h	enhances the antiproliferative effect of erlotinib	26675484
ACHN	10/25/50 nM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner synergistically with ritonavir	25279191
ACHN	50 nM	Apoptosis Assay	48 h	induces cell apoptosis combined ritonavir	25279191
ACHN	25/50 nM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner synergistically with bortezomib	25176354
ACHN	50 nM	Colony Formation Assay	7-14 d	suppressed colony formation significantly combined with with bortezomib	25176354
ACHN	50 nM	Apoptosis Assay	48 h	induces cell apoptosis	25176354
AML3	0-1 μM	Function Assay	24 h	induces DNA fragmentation in a dose-dependent manner	25612941
BHP2-7		Growth Inhibition Assay		IC50=37 ± 6 nM	23824064
BT-549	10 nM	Morphological Crystal Violet (CV) Assay	3 d	alters cell morphology	24810497
C643		Growth Inhibition Assay		IC50=71 ± 10 nM	23824064
Caki-1	10/25/50 nM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner synergistically with ritonavir	25279191
Caki-1	50 nM	Apoptosis Assay	48 h	induces cell apoptosis combined ritonavir	25279191
Caki-1	25/50 nM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner synergistically with bortezomib	25176354
Caki-1	50 nM	Colony Formation Assay	7-14 d	suppressed colony formation significantly combined with with bortezomib	25176354
Caki-1	50 nM	Apoptosis Assay	48 h	induces cell apoptosis	25176354
Cal62		Growth Inhibition Assay		IC50=33 ± 4 nM	23824064
Capan-1	25/50/100 nM	Function Assay	8/24/48 h	downregulated Ron mRNA and protein expression and downstream signaling	23922886
Capan-1	25/50/100 nM	Growth Inhibition Assay	48 h	reduces cell growth in a dose-dependent manner	23922886
Capan-1	25/50/100 nM	Apoptosis Assay	48 h	induces cell growth in a dose-dependent manner	23922886
CFPAC-1	25/50/100 nM	Function Assay	8/24/48 h	downregulated Ron mRNA and protein expression and downstream signaling	23922886
CFPAC-1	25/50/100 nM	Growth Inhibition Assay	48 h	reduces cell growth in a dose-dependent manner	23922886
CFPAC-1	25/50/100 nM	Apoptosis Assay	48 h	induces cell growth in a dose-dependent manner	23922886
cH630 5-FU-res		Growth Inhibition Assay	72 h	IC50=15.5 ± 1.2 nM	23299388
CTS	0–40 nM	Apoptosis Assay	48 h	induces apoptosis in a dose-dependent manner	24244429
dHCT116 p21−/−		Growth Inhibition Assay	72 h	IC50=5.9 ± 1.3 nM	23299388
eSW620		Growth Inhibition Assay	72 h	IC50=9.1 ± 2.1 nM	23299388
FaDu	100 nM	Growth Inhibition Assay	8/10/12 h	displayed a significant and prolonged G2/M arrest at 8 and 12 h post release	24026482
FaDu	100 nM	Function Assay	2/4/8/12 h	induced p21Waf1/Cip1 expression	24026482
G401	0.01–10.0 μM	Growth Inhibition Assay	24 h	IC50=143.02 nM	26176219
G401	50 nM	Cell Viability Assay	1–4 d	reduces cell survival in a time dependent manner	26176219
G401	50/100 nM	Apoptosis Assay	24 h	induces cell apoptosis in a dose-dependent manner	26176219
G401	50/100 nM	Function Assay	24 h	shows the induction of DNA fragmentation	26176219
G401	50/100 nM	Function Assay	24 h	induces cell cycle disorder	26176219
H630		Growth Inhibition Assay	72 h	IC50=12.4 ± 3.1 nM	23299388
H929	2/4/6 nM	Cell Survival Assay	48 h	induces a significant decrease in the cell growth	26000292
HCC827	5/7.5/10 nM	Growth Inhibition Assay	72 h	enhances the antiproliferative effect of erlotinib	26675484
HCC827	10 nM	Growth Inhibition Assay	48 h	enhances cisplatin sensitivity	25944617
HCC-LM3	1-1000 nM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth in both time- and dose-dependent manner	24093956
HCC-LM3	50 nM	Apoptosis Assay	48 h	induces cell apoptosis significantly in a caspase-dependent manner by cleavage of caspases 3, 8 and 9	24093956
HCC-LM3	50/100 nM	Function Assay	24 h	decreases the levels of p-STAT3 and p-Akt	24093956
HCC-LM3	50/100 nM	Function Assay	24 h	downregulates Bcl-xL expression	24093956
HCT116		Growth Inhibition Assay	72 h	IC50=10.7 ± 2.2 nM	23299388
HCT116 p53−/−		Growth Inhibition Assay	72 h	IC50=8.6 ± 1.7 nM	23299388
HCT8		Growth Inhibition Assay	72 h	IC50=12.9 ± 1.9 nM	23299388
HepG2	0-10 μM	Growth Inhibition Assay	0-4 d	inhibits cell growth in both time- and dose-dependent manner	26702784
HepG2	50 nM	Function Assay	24-72 h	induced activation of caspase 3 after 24 h	26702784
HepG2	1-1000 nM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth in both time- and dose-dependent manner	24093956
HepG2	50 nM	Apoptosis Assay	48 h	induces cell apoptosis significantly in a caspase-dependent manner by cleavage of caspases 3, 8 and 9	24093956
HepG2	50/100 nM	Function Assay	24 h	decreases the levels of p-STAT3 and p-Akt	24093956
HepG2	50/100 nM	Function Assay	24 h	downregulates Bcl-xL expression	24093956
HN22	0-20 nM	Growth Inhibition Assay	24/48 h	inhibits cell viability in both time- and dose- dependent manner	23877235
HN22	0-20 nM	Apoptosis Assay	48 h	induces cell apoptosis	23877235
HN22	0-20 nM	Growth Inhibition Assay	48 h	induces G1 phase cell cycle arrest	23877235
HN22	0-20 nM	Function Assay	48 h	suppresses Sp1 expression	23877235
HSC4	0-20 nM	Growth Inhibition Assay	24/48 h	inhibits cell viability in both time- and dose- dependent manner	23877235
HSC4	0-20 nM	Apoptosis Assay	48 h	induces cell apoptosis	23877235
HSC4	0-20 nM	Growth Inhibition Assay	48 h	induces G1 phase cell cycle arrest	23877235
HSC4	0-20 nM	Function Assay	48 h	suppresses Sp1 expression	23877235
HT29	0-10 μM	Growth Inhibition Assay	0-4 d	inhibits cell growth in both time- and dose-dependent manner	26702784
HT29	50 nM	Function Assay	24-72 h	induced activation of caspase 3 after 48 h	26702784
HT29		Growth Inhibition Assay	72 h	IC50=16.3 ± 2.3 nM	23299388
Hth7		Growth Inhibition Assay		IC50=15 ± 2 nM	23824064
Hth83		Growth Inhibition Assay		IC50=34 ± 5 nM	23824064
J89GFP		Growth Inhibition Assay		EC50=49.85 ± 12.65 nM	26563568
L3.6pl	25/50/100 nM	Function Assay	8/24/48 h	downregulated Ron mRNA and protein expression and downstream signaling	23922886
L3.6pl	25/50/100 nM	Growth Inhibition Assay	48 h	reduces cell growth in a dose-dependent manner	23922886
L3.6pl	25/50/100 nM	Apoptosis Assay	48 h	induces cell growth in a dose-dependent manner	23922886
LNCaP	0-5 μM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth in both time- and dose-dependent manner	23991216
LoVo		Growth Inhibition Assay	72 h	IC50=5.1 ± 0.6 nM	23299388
MCF-7	10 nM	Morphological Crystal Violet (CV) Assay	3 d	alters cell morphology	24810497
MCF-7	5-50 nM	Function Assay	24 h	reduced the level of expression of ERα, PR and FoxA1	24366407
MDA-MB-231	10 nM	Morphological Crystal Violet (CV) Assay	3 d	alters cell morphology	24810497
ML-1	0-1 μM	Function Assay	24 h	induces DNA fragmentation in a dose-dependent manner	25612941
ML-1	1 μM	Function Assay	24 h	increases caspase-3 activity 4-fold	25612941
NCI-H23	10 nM	Growth Inhibition Assay	48 h	enhances cisplatin sensitivity	25944617
NCI-H460	10/20/30 nM	Growth Inhibition Assay	72 h	enhances the antiproliferative effect of erlotinib	26675484
OCI-AML3	0–40 nM	Apoptosis Assay	48 h	induces apoptosis in a dose-dependent manner	24244429
OPM2	2/4/6 nM	Cell Survival Assay	48 h	induces a significant decrease in the cell growth	26000292
OS-RC-2	0-1000 nM	Cell Viability Assay	24/48/72 h	decreases cell viability in both time- and dose-dependent manner	24144737
OS-RC-2	50 nM	Growth Inhibition Assay	48 h	induces G2/M arrest	24144737
OS-RC-2	50 nM	Apoptosis Assay	48 h	induces cell apoptosis	24144737
PC3	0-100 nM	Apoptosis Assay	24/48 h	induces apoptosis in a dose-dependent manner	24163230
PC3	0-100 nM	Growth Inhibition Assay	24/48 h	induces accumulation of subG1 population	24163230
PC3	0-100 nM	Function Assay	24 h	suppresses expression of activated ATM, Akt and Erk1/2 protein	24163230
PC-3	0-10 μM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth in both time- and dose-dependent manner	23991216
PC3-AR	0-100 nM	Apoptosis Assay	24/48 h	induces apoptosis in both time- and dose-dependent manner	24163230
PC3-AR	0-100 nM	Growth Inhibition Assay	24/48 h	induces cell cycle arrest in the G2M phase	24163230
PC3-AR	0-100 nM	Function Assay	24 h	suppresses expression of activated ATM, Akt and Erk1/2 protein	24163230
RKO		Growth Inhibition Assay	72 h	IC50=7.9 ± 2.2 nM	23299388
RPMI 8226	2/4/6 nM	Cell Survival Assay	48 h	induces a significant decrease in the cell growth	26000292
RPMI 8226	4 nM	Apoptosis Assay	24/48 h	induces cell apoptosis in a time-dependent manner	26000292
RPMI-8226vr10	0-1 μM	Function Assay	24 h	induces DNA fragmentation in a dose-dependent manner	25612941
RPMI-8226vr10	1 μM	Function Assay	24 h	increases caspase-3 activity 2.5-fold	25612941
RWPE-1	0-20 μM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth in both time- and dose-dependent manner	23991216
SK-N-AS		Growth Inhibition Assay	24 h	IC50=37.1 ± 2.4 nM	25308916
SK-N-AS	0–80 nM	Growth Inhibition Assay	48 h	IC50=27.4 nM	24098799
SK-N-AS	0–80 nM	Apoptosis Assay	48 h	potently induced apoptosis in a dose-dependent fashion	24098799
SK-N-AS	0–80 nM	Function Assay	48 h	induces a dose-dependent cleavage of caspase 3 and PARP	24098799
SK-N-BE	0–80 nM	Growth Inhibition Assay	48 h	IC50=75.4 nM	24098799
SK-N-BE	0–40 nM	Apoptosis Assay	48 h	potently induced apoptosis in a dose-dependent fashion	24098799
SK-N-BE	0–40 nM	Function Assay	48 h	induces a dose-dependent cleavage of caspase 3 and PARP	24098799
SK-N-BE (2)		Growth Inhibition Assay	24 h	IC50=104.0 ± 7.8 nM	25308916
SK-N-BE (2), MK PAN		Growth Inhibition Assay	24 h	IC50=382.0 ± 43.2 nM	25308916
SK-N-BE (2), PAN MK		Growth Inhibition Assay	24 h	IC50=104.0 ± 7.8 nM	25308916
SK-N-DZ		Growth Inhibition Assay	24 h	IC50=17.1 ± 0.4 nM	25308916
SK-N-DZ	0–80 nM	Growth Inhibition Assay	48 h	IC50=21.9 nM	24098799
SK-N-DZ	0–80 nM	Apoptosis Assay	48 h	potently induced apoptosis in a dose-dependent fashion	24098799
SK-N-DZ	0–80 nM	Function Assay	48 h	induces a dose-dependent cleavage of caspase 3 and PARP	24098799
SK-NEP-1	0.01–10.0 μM	Growth Inhibition Assay	24 h	IC50=76.34 nM	26176219
SK-NEP-1	50 nM	Cell Viability Assay	1–4 d	reduces cell survival in a time dependent manner	26176219
SK-NEP-1	50/100 nM	Apoptosis Assay	24 h	induces cell apoptosis in a dose-dependent manner	26176219
SK-NEP-1	50/100 nM	Function Assay	24 h	shows the induction of DNA fragmentation	26176219
SK-NEP-1	50/100 nM	Function Assay	24 h	induces cell cycle disorder	26176219
SK-N-SH	0–80 nM	Growth Inhibition Assay	48 h	IC50=72.3 nM	24098799
SK-N-SH	0–40 nM	Apoptosis Assay	48 h	potently induced apoptosis in a dose-dependent fashion	24098799
SK-N-SH	0–40 nM	Function Assay	48 h	induces a dose-dependent cleavage of caspase 3 and PARP	24098799
SMMC-7721	1-1000 nM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth in both time- and dose-dependent manner	24093956
SMMC-7721	50 nM	Apoptosis Assay	48 h	induces cell apoptosis significantly in a caspase-dependent manner by cleavage of caspases 3, 8 and 9	24093956
SMMC-7721	50/100 nM	Function Assay	24 h	decreases the levels of p-STAT3 and p-Akt	24093956
SMMC-7721	50/100 nM	Function Assay	24 h	downregulates Bcl-xL expression	24093956
SW1736		Growth Inhibition Assay		IC50=35 ± 8 nM	23824064
SW480		Growth Inhibition Assay	72 h	IC50=17.5 ± 0.8 nM	23299388
T238		Growth Inhibition Assay		IC50=1,500 ± 200 nM	23824064
T241		Growth Inhibition Assay		IC50=65 ± 7 nM	23824064
T351		Growth Inhibition Assay		IC50=50 ± 10 nM	23824064
THP89GFP		Growth Inhibition Assay		EC50=19.34 ± 6.43 nM	26563568
U266	2/4/6 nM	Cell Survival Assay	48 h	induces a significant decrease in the cell growth	26000292
U937	0–40 nM	Apoptosis Assay	48 h	induces apoptosis in a dose-dependent manner	24244429

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02506959	Plasma Cell Leukemia ... 展开 >> Plasmacytoma Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma 收起 <<	Phase 2	Recruiting	September 14, 2019	United States, Texas ... 展开 >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Yago L. Nieto 713-792-8750 ynieto@mdanderson.org Principal Investigator: Yago L. Nieto 收起 <<
NCT00449761	Leukemia, Myeloid, Chronic	Phase 2 Phase 3	Completed	-	-
NCT01055483	Acute Myeloid Leukemia	Phase 1	Completed	-	France ... 展开 >> Novartis Investigative Site Paris Cedex 4, France, 75181 Novartis Investigative Site Paris, France, 75475 Germany Novartis Investigative Site Dresden, Germany, 01307 Novartis Investigative Site Frankfurt, Germany, 60590 Novartis Investigative Site Hannover, Germany, 30625 Novartis Investigative Site Ulm, Germany, 89081 收起 <<
NCT00936611	Waldenstrom's Macroglobulinemi... 展开 >>a 收起 <<	Phase 2	Active, not recruiting	December 2021	United States, Colorado ... 展开 >> Rocky Mountain Cancer Centers Denver, Colorado, United States, 80220 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT00880269	Refractory Leukemia ... 展开 >> Acute Myelogenous Leukemia 收起 <<	Phase 2	Completed	-	-
NCT02802163	Multiple Myeloma	Phase 1 Phase 2	Withdrawn(study drug unavailab... 展开 >>le) 收起 <<	December 2020	-
NCT00493766	Hormone Refractory Prostate Ca... 展开 >>ncer 收起 <<	Phase 1	Terminated(Because of a strate... 展开 >>gic decision by Novartis) 收起 <<	-	United States, Massachusetts ... 展开 >> Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115-6-84 United States, Missouri Washing University School of Medicine St. Louis, Missouri, United States, 63110 United States, Nevada Nevada Cancer Institute Las Vegas, Nevada, United States, 89135 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27705 收起 <<
NCT02145715	Multiple Myeloma	Phase 1 Phase 2	Unknown	January 2016	United Kingdom ... 展开 >> Birmingham Heartlands Hospital Birmingham, UK, United Kingdom, B9 5SS Royal Liverpool University Hospital Liverpool, United Kingdom, L7 8XP St Bartholomew's Hospital London, United Kingdom, EC1A 7BE University College London Hospitals NHS Foundation Trust London, United Kingdom, WC1E 6AG Guy's Hospital London, United Kingdom 收起 <<
NCT00880269	-		Completed	-	-
NCT00918333	Adult Nasal Type Extranodal NK... 展开 >>/T-cell Lymphoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma B-cell Adult Acute Lymphoblastic Leukemia Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Hepatosplenic T-cell Lymphoma Nodal Marginal Zone B-cell Lymphoma Post-transplant Lymphoproliferative Disorder Primary Central Nervous System Non-Hodgkin Lymphoma Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Hodgkin Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Adult T-cell Leukemia/Lymphoma Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Mycosis Fungoides/Sezary Syndrome Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Multiple Myeloma Splenic Marginal Zone Lymphoma T-cell Adult Acute Lymphoblastic Leukemia Waldenström Macroglobulinemia 收起 <<	Phase 1 Phase 2	Active, not recruiting	December 2018	United States, Arizona ... 展开 >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, Maryland Mark O Hatfield-Warren Grant Magnuson Clinical Center Bethesda, Maryland, United States, 20892 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT00918333	-		Active, not recruiting	-	-
NCT00738751	Lung Cancer H... 展开 >>ead and Neck Cancer 收起 <<	Phase 1	Completed	-	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States, 33612 收起 <<
NCT01111526	Graft-Versus-Host Disease	Phase 1 Phase 2	Completed	-	United States, Florida ... 展开 >> H Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 收起 <<
NCT00878436	Prostate Cancer ... 展开 >> Prostatic Neoplasms 收起 <<	Phase 1 Phase 2	Completed	-	United States, New Jersey ... 展开 >> The Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, New York North Shore University Hospital-Monter Cancer Center Lake Success, New York, United States, 11042 NYU Cancer Center New York, New York, United States, 10016 United States, Oregon Oregon Health & Science University Portland, Oregon, United States, 97239 收起 <<
NCT01111526	-		Completed	-	-
NCT00777335	Breast Cancer	Phase 2	Terminated(Very low recruiteme... 展开 >>nt rate.) 收起 <<	-	United States, California ... 展开 >> UCLA Los Angeles, California, United States, 90095-1678 收起 <<
NCT01055795	Advanced Solid Tumors	Phase 1	Completed	-	United States, North Carolina ... 展开 >> Duke University Medical Center Durham, North Carolina, United States, 27710 收起 <<
NCT00873002	Liver Cancer	Phase 1	Terminated(Dose Limiting Toxic... 展开 >>ity) 收起 <<	-	United States, Ohio ... 展开 >> Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 收起 <<
NCT02204553	-		-	-	-
NCT01090973	Non-Hodgkin's Lymphoma	Phase 2	Terminated(Pharmaceutical comp... 展开 >>any request.) 收起 <<	-	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 收起 <<
NCT00878436	-		Completed	-	-
NCT01090973	-		Terminated(Pharmaceutical comp... 展开 >>any request.) 收起 <<	-	-
NCT00788931	HER-2 Positive Breast Cancer ... 展开 >> Metastatic Breast Cancer 收起 <<	Phase 1	Completed	-	United States, Alabama ... 展开 >> Novartis Investigative Site Mobile, Alabama, United States, 36688 Australia, South Australia Novartis Investigative Site Woodville, South Australia, Australia, 5011 Belgium Novartis Investigative Site Bruxelles, Belgium, 1000 Novartis Investigative Site Liege, Belgium, 4000 Italy Novartis Investigative Site Macerata, MC, Italy, 62100 Novartis Investigative Site Aviano, PN, Italy, 33081 Netherlands Novartis Investigative Site Amsterdam, Netherlands, 1066 CX 收起 <<
NCT00859222	-		Completed	-	-
NCT01169636	Hodgkin's Lymphoma	Phase 1 Phase 2	Completed	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01083602	Relapsed and Bortezomib Refrac... 展开 >>tory Multiple Myeloma Refractory Multiple Myeloma Multiple Myeloma in Relapse 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> University of California at Los Angeles Los Angeles, California, United States, 90095 Stanford University Medical Center Division of Hematology Stanford, California, United States, 94305-5826 United States, Florida H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States, 33612 United States, Georgia Emory University School of Medicine/Winship Cancer Institute Dept. of Winship Cancer Inst. Atlanta, Georgia, United States, 30322 Georgia Regents University MedCollege of GA Cancer Ctr 2 Augusta, Georgia, United States, 30912 United States, Illinois Hematology/Oncology of the North Shore Orchard Healthcare Res. Inc. Skokie, Illinois, United States, 60076 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New Jersey Somerset Hematology Oncology Associates Somerset Hema Oncol Assoc (2) Somerset, New Jersey, United States, 08873 United States, New York Montefiore Medical Center Bronx, New York, United States, 10467 United States, North Carolina Duke University Medical Center Dept. of DUMC (4) Durham, North Carolina, United States, 27710 United States, Tennessee Vanderbilt University Medical Center, Clinical Trials Center Vanderbilt UMC Nashville, Tennessee, United States, 37212 United States, Texas MD Anderson Cancer Center/University of Texas MD Anderson CC Houston, Texas, United States, 77030 United States, Wisconsin Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226 收起 <<
NCT00859222	Malignant Glioma	Phase 1 Phase 2	Completed	-	United States, Illinois ... 展开 >> Northwestern University Chicago, Illinois, United States, 60611 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Beth-Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Virginia University of Virginia, Department of Neurology Charlottesville, Virginia, United States, 22908 收起 <<
NCT01083602	-		Completed	-	-
NCT00532389	Multiple Myeloma	Phase 1	Completed	-	United States, Florida ... 展开 >> Innovative Medical Research of South Florida Dept.ofInnovativeMedResearch Miami Shores, Florida, United States, 33138 United States, Massachusetts Dana Farber Cancer Institute Clinical Research Coordinator Boston, Massachusetts, United States, 02115 United States, New Jersey Hackensack University Medical Center Multiple Myeloma Division Hackensack, New Jersey, United States, 07601 United States, Washington Swedish Medical Center Dept.ofSwedishMedicalCtr. Seattle, Washington, United States Australia, Australian Capital Territory Novartis Investigative Site Canberra, Australian Capital Territory, Australia, 2606 Canada, British Columbia Novartis Investigative Site Vancouver, British Columbia, Canada, V5Z 1M9 Canada, Quebec Novartis Investigative Site Montreal, Quebec, Canada, H1T 2M4 Germany Novartis Investigative Site Berlin, Germany, 10117 Novartis Investigative Site Kiel, Germany, 24105 Novartis Investigative Site Leipzig, Germany, 04103 Novartis Investigative Site München, Germany, 80336 Novartis Investigative Site Wuerzburg, Germany, 97070 Italy Novartis Investigative Site Bologna, BO, Italy, 40138 Novartis Investigative Site Torino, TO, Italy, 10126 Spain Novartis Investigative Site Salamanca, Castilla y Leon, Spain, 37007 Novartis Investigative Site Barcelona, Catalunya, Spain, 08036 收起 <<
NCT00777335	-		Terminated(Very low recruiteme... 展开 >>nt rate.) 收起 <<	-	-
NCT02676323	Acute Myeloid Leukemia ... 展开 >> Myelodysplastic Syndrome 收起 <<	Phase 1	Terminated(Slow accrual)	-	United States, California ... 展开 >> Children's Hospital Los Angeles Los Angeles, California, United States, 90027 Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States, 94304 Rady Children's Hospital and Health Center San Diego, California, United States, 92123 United States, Michigan Children's Hospital of Michigan Detroit, Michigan, United States, 48201 United States, Tennessee St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 United States, Texas Cook Children's Medical Center Fort Worth, Texas, United States, 76104 United States, Washington Seattle Children's Hospital Seattle, Washington, United States, 98105 收起 <<
NCT01005797	Renal Cancer ... 展开 >>Non Small Cell Lung Cancer (NSCLC) Soft Tissue Sarcoma 收起 <<	Phase 1	Completed	-	United States, South Carolina ... 展开 >> Medical University of South Carolina Hollings Cancer Center Charleston, South Carolina, United States, 29425 收起 <<
NCT02057640	Multiple Myeloma ... 展开 >> Kahler Disease Plasma-Cell Myeloma Myelomatosis 收起 <<	Phase 1 Phase 2	Active, not recruiting	December 2018	United States, Ohio ... 展开 >> University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106 Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 收起 <<
NCT00686218	Leukemia	Phase 1	Completed	-	United States, California ... 展开 >> City of Hope Medical Center Duarte, California, United States, 91010-3000 South Pasadena Cancer Center South Pasadena, California, United States, 91030 United States, Washington Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 收起 <<
NCT00445068	Multiple Myeloma	Phase 2	Terminated	-	-
NCT02290431	Relapse/Refractory Multiple My... 展开 >>eloma 收起 <<	Phase 2	Recruiting	July 8, 2019	Japan ... 展开 >> Nagoya City University Hospital Recruiting Nagoya City, Aichi, Japan, 467-8602 Novartis Investigative Site Completed Kashiwa-city, Chiba, Japan, 277-8567 Matsuyama Red Cross Hospital Recruiting Matsuyama-City, Ehime, Japan, 790-8524 Novartis Investigative Site Terminated Fukuoka city, Fukuoka, Japan, 812-8582 Novartis Investigative Site Recruiting Ogaki-city, Gifu, Japan, 503-8502 Gunma University Hospital Recruiting Maebashi-city, Gunma, Japan, 371-8511 Principal Investigator: Hiroshi Handa, M.D. Novartis Investigative Site Recruiting Shibukawa-city, Gunma, Japan, 377-0280 Novartis Investigative Site Completed Kure-city, Hiroshima, Japan, 737-0023 Kobe City Medical Center General Hospital Recruiting Kobe, Hyogo, Japan, 650-0047 Mito Medical Center Recruiting Higashiibaraki-gun, Ibaraki, Japan, 311-3193 University Hospital, Kyoto Prefectural, University of Medicine Recruiting Kamigyo-ku, Kyoto, Japan, 602-8566 Novartis Investigative Site Recruiting Sendai-shi, Miyagi, Japan, 983 8520 Niigatq Cancer Ce3nter Hospital Recruiting Kawagishi-cho, Chuo-ku, Niigata, Japan, 951-8566 Novartis Investigative Site Completed Okayama-city, Okayama, Japan, 701-1192 Osaka University Hospital Recruiting Yamadaoka, Suita-City, Osaka, Japan, 565-0871 Novartis Investigative Site Completed Utsunomiya-shi, Tochigi, Japan, 320-0834 Tokushima University Hospital Recruiting Tokushima-City, Tokushima, Japan, 770-8503 Novartis Investigative Site Completed Koto-ku, Tokyo, Japan, 135 8550 Japanese Red Cross Medical Center Recruiting Shibuya-Ku, Tokyo, Japan, 150-8935 Center Hospital of the National Center for Global Health and Medicine Recruiting Shinjuku-ku, Tokyo, Japan, 162-8655 Principal Investigator: Akiyoshi Miwa, M.D. Novartis Investigative Site Recruiting Tachikawa, Tokyo, Japan, 190-0014 Novartis Investigative Site Recruiting Aomori, Japan, 030 8553 收起 <<
NCT01324635	Recurrent Glioma ... 展开 >> High-grade Meningioma Brain Metastasis 收起 <<	Phase 1	Terminated(Arm A - reached goa... 展开 >>l; Arm B - poor accrual) 收起 <<	-	United States, Pennsylvania ... 展开 >> Thomas Jefferson University Philadelphia, Pennsylvania, United States, 19107 收起 <<
NCT03256045	Recurrent Plasma Cell Myeloma ... 展开 >> Refractory Plasma Cell Myeloma 收起 <<	Phase 2	Recruiting	May 16, 2024	United States, Washington ... 展开 >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Pamela S. Becker 206-606-7273 pbecker@u.washington.edu Principal Investigator: Pamela S. Becker 收起 <<
NCT01034657	-		Terminated(The study was termi... 展开 >>nated due to lack of efficacy of single agent LBH589 in the 4 month open label core phase and due to enrollment difficulties.) 收起 <<	-	-
NCT00667862	Prostate Cancer	Phase 2	Completed	-	United States, Maryland ... 展开 >> University of Maryland Baltimore, Maryland, United States, 21201 Johns Hopkins Hospital Baltimore, Maryland, United States, 21287 United States, Missouri Washington University St. Louis, Missouri, United States, 63130 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Wisconsin University of Wisconsin Madison, Wisconsin, United States, 53706-1481 收起 <<
NCT01034657	Myelodysplastic Syndrome (MDS)	Phase 2	Terminated(The study was termi... 展开 >>nated due to lack of efficacy of single agent LBH589 in the 4 month open label core phase and due to enrollment difficulties.) 收起 <<	-	Germany ... 展开 >> Novartis Investigative Site Mannheim, Baden-Württemberg, Germany, 68305 Novartis Investigative Site Berlin, Germany, 12203 Novartis Investigative Site Bonn, Germany, 53105 Novartis Investigative Site Dresden, Germany, 01307 Novartis Investigative Site Duesseldorf, Germany, 40225 Novartis Investigative Site Duisburg, Germany, 47166 Novartis Investigative Site Frankfurt, Germany, 60590 Novartis Investigative Site Goettingen, Germany, 37075 Novartis Investigative Site Hannover, Germany, 30625 Novartis Investigative Site Leipzig, Germany, 04103 Novartis Investigative Site Muenchen, Germany, 81675 Novartis Investigative Site Ulm, Germany, 89081 收起 <<
NCT02756663	Multiple Myeloma	Phase 2	Withdrawn	February 2021	-
NCT01159418	Advanced Solid Tumors	Phase 1	Unknown	March 2012	Switzerland ... 展开 >> Huniversitätsspitals Basel Basel, Switzerland, 4031 Istituto Oncologico della Svizzera Italiana Bellinzona, Switzerland, 6500 Mèdecin Adjoint, ME - CePO, CHUV Lausanne, Switzerland, 1011 收起 <<
NCT00472368	Cancer Patients With Advanced ... 展开 >>Solid Tumors Including Lymphoma or Chronic Hematological Malignancies 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Novartis Investigative Site Buffalo, New York, United States, 14263 收起 <<
NCT00490776	Cutaneous T-Cell Lymphoma	Phase 2 Phase 3	Completed	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham/ The Kirklin Clinic Birmingham, Alabama, United States, 35233 United States, California UCLA Medical Center School of Medicine/ Dpt of Hematology-Oncology Los Angeles, California, United States, 90095 United States, Colorado University of Colorado Health Sciences Center/Anschutz Cancer Pavillion Aurora, Colorado, United States, 80010 United States, Florida Florida Academic Dermatology Centers Miami, Florida, United States, 33136 United States, Georgia Medical College of Georgia Augusta, Georgia, United States, 30912 United States, Illinois Rush Presbyterian Hospital/St. Luke's Medical Center Chicago, Illinois, United States, 60612 United States, Missouri St. Louis University Cancer Cennter St. Louis, Missouri, United States, 63110 United States, Nebraska Nebraska Medical Center Omaha, Nebraska, United States, 68198 United States, New York Our Lady of Mercy Medical Center/Comprehensive Cancer Center Bronx, New York, United States, 10466 Roswell Park Cancer Institute Buffalo, New York, United States, 14263 NYU Clinical Cancer Center New York, New York, United States, 10016 United States, North Carolina Wake University Health Sciences Winston-Salem, North Carolina, United States, 27157 United States, Oklahoma University of Oklahoma-Tulsa Tulsa, Oklahoma, United States, 74104 United States, Oregon Craig Okada Portland, Oregon, United States, 97239 United States, Pennsylvania University of Pittsburg Medical Center Pittsburg, Pennsylvania, United States, 15213 United States, Tennessee The Jones Clinic Germantown, Tennessee, United States, 38138 United States, Texas MD Anderson Cancer Center/University of Texas Houston, Texas, United States, 77030 United States, Washington Seattle Cancer Care Alliance Seattle, Washington, United States, 98109-102 收起 <<
NCT01238692	Diffuse Large B Cell Lymphoma	Phase 2	Unknown	December 2016	Canada, Nova Scotia ... 展开 >> Queen Elizabeth II Health Sciences Centre Halifax, Nova Scotia, Canada, H3T 1E2 Canada, Ontario Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Sacré-Cœur Hospital Montreal, Quebec, Canada, H4J 1C5 收起 <<
NCT02588339	Graft Versus Host Disease ... 展开 >> GVHD 收起 <<	Phase 2	Active, not recruiting	December 2020	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 收起 <<
NCT01056601	-		Terminated(Funding not availab... 展开 >>le) 收起 <<	-	-
NCT01056601	Pancreatic Cancer	Phase 2	Terminated(Funding not availab... 展开 >>le) 收起 <<	-	United States, Minnesota ... 展开 >> Masonic Cancer Center, University of Minnesota Minneapolis, Minnesota, United States, 55455 收起 <<
NCT01032148	Hodgkin's Lymphoma ... 展开 >> Non-Hodgkin's Lymphoma 收起 <<	Phase 1	Terminated(lack of funding)	-	United States, New York ... 展开 >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 收起 <<
NCT02720510	-		Terminated(A study was termina... 展开 >>ted due to low enrollment.) 收起 <<	-	-
NCT00412997	Tumors Cutane... 展开 >>ous T-Cell Lymphoma 收起 <<	Phase 1	Completed	-	Japan ... 展开 >> Novartis Investigative Site Tokyo, Japan 收起 <<
NCT02720510	Multiple Myeloma	Phase 2	Terminated(A study was termina... 展开 >>ted due to low enrollment.) 收起 <<	-	United States, California ... 展开 >> David Geffen School of Medicine at UCLA UCLA Los Angeles, California, United States, 90095 United States, Florida Memorial West Cancer Center Memorial Cancer Institute Pembroke Pines, Florida, United States, 33028 United States, Georgia Northside Hospital Central Research Dept. Atlanta, Georgia, United States, 30342 United States, Nebraska Oncology Hematology West Nebraska Cancer Specialists dbaNebraska Cancer Specialists Omaha, Nebraska, United States, 68124 United States, Texas Brooke Army Medical Center Hematology/Oncology San Antonio, Texas, United States, 78234 收起 <<
NCT01440582	Myeloma	Phase 1	Active, not recruiting	February 1, 2019	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01034163	-		Completed	-	-
NCT00891033	Multiple Myeloma	Phase 1	Terminated(This study was term... 展开 >>inated because the drug company stopped making the study drug) 收起 <<	-	United States, Arkansas ... 展开 >> Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences Little Rock, Arkansas, United States, 72205 收起 <<
NCT01007968	Advanced Solid Tumors	Phase 1	Completed	-	United States, Utah ... 展开 >> University of Utah / Huntsman Cancer Institute Salt Lake City, Utah, United States, 84103 Netherlands Novartis Investigative Site Leiden, Netherlands, 2300 RC Sweden Novartis Investigative Site Lund, Sweden, SE-221 85 Novartis Investigative Site Stockholm, Sweden, SE-171 76 Switzerland Novartis Investigative Site St. Gallen, Switzerland, 9007 United Kingdom Novartis Investigative Site Edinburgh, United Kingdom, EH4 2XR 收起 <<
NCT01965353	Multiple Myeloma in Relapse	Phase 1	Active, not recruiting	December 2019	United States, Massachusetts ... 展开 >> Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 收起 <<
NCT01034163	Hodgkin's Lymphoma	Phase 3	Completed	-	-
NCT00503451	Non-Hodgkin Lymphoma ... 展开 >> Neoplasms 收起 <<	Phase 1	Completed	-	United States, Nevada ... 展开 >> Nevada Cancer Institute Las Vegas, Nevada, United States, 89135 Netherlands Novartis Investigative Site Rotterdam, Netherlands 收起 <<
NCT00946647	Myelodysplastic Syndromes ... 展开 >> Chronic Myelomonocytic Leukemia Acute Myeloid Leukemia 收起 <<	Phase 1	Active, not recruiting	June 13, 2019	-
NCT00567879	Breast Cancer	Phase 1 Phase 2	Terminated(The study was termi... 展开 >>nated early due to insufficient evidence of clinical benefit.) 收起 <<	-	United States, California ... 展开 >> University of California at Los Angeles Los Angeles, California, United States, 90095 United States, Colorado University of Colorado Dept. of Univ. of Colorado Aurora, Colorado, United States, 80045 United States, Connecticut Norwalk Hospital Dept of Norwalk Hospital (2) Norwalk, Connecticut, United States, 06856 United States, Maryland VA Maryland Health Care Dept.of GreenbaumCancerCent(3) Baltimore, Maryland, United States, 21201 United States, Missouri The Center for Cancer Care and Research St. Louis, Missouri, United States, 63141 United States, Ohio Ohio State Comprehensive Cancer Center/James Cancer Hospital SC Columbus, Ohio, United States, 43210 United States, Pennsylvania University of Pittsburgh Cancer Institute Dept of Magee Women's Hospital Pittsburgh, Pennsylvania, United States, 15232 Canada, British Columbia Novartis Investigative Site Kelowna, British Columbia, Canada, V1Y 5L3 Canada, Ontario Novartis Investigative Site Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Novartis Investigative Site Montreal, Quebec, Canada, H3T 1E2 France Novartis Investigative Site Dijon Cedex, France, 21034 Novartis Investigative Site Paris, France, 75231 Novartis Investigative Site Saint-Herblain Cédex, France, 44805 Germany Novartis Investigative Site Heidelberg, Germany, 69115 Italy Novartis Investigative Site Meldola, FC, Italy, 47014 Novartis Investigative Site Genova, GE, Italy, 16132 Novartis Investigative Site Modena, MO, Italy, 41100 United Kingdom Novartis Investigative Site Birmingham, United Kingdom, B15 2TH Novartis Investigative Site London, United Kingdom, W12 0HS Novartis Investigative Site Manchester, United Kingdom, M20 4BX 收起 <<
NCT01028313	Chronic Graft-Versus-Host Dise... 展开 >>ase 收起 <<	Phase 2	Withdrawn(A decision was made ... 展开 >>to not move forward with the study. No participants were enrolled or treated.) 收起 <<	-	United States, Tennessee ... 展开 >> Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 收起 <<
NCT00632489	-		Completed	-	-
NCT00567879	-		Terminated(The study was termi... 展开 >>nated early due to insufficient evidence of clinical benefit.) 收起 <<	-	-
NCT00777049	Breast Cancer	Phase 2	Completed	-	United States, California ... 展开 >> UCLA Los Angeles, California, United States, 90095-1678 收起 <<
NCT00777049	-		Completed	-	-
NCT01463046	Acute Myeloid Leukemia ... 展开 >> Advanced Myelodysplastic Syndrome 收起 <<	Phase 1	Active, not recruiting	December 2018	United States, California ... 展开 >> UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94143 收起 <<
NCT00594230	Myelodysplastic Syndromes (MDS... 展开 >>) 收起 <<	Phase 2	Terminated(Per protocol, the r... 展开 >>esults of a planned interim analysis demonstrated insufficient efficacy and led to early termination of the study.) 收起 <<	-	United States, Florida ... 展开 >> Florida Cancer Specialists Fort Myers, Florida, United States, 33901 United States, Georgia Northeast Georgia Medical Center Gainesville, Georgia, United States, 30501 United States, Kentucky Consultants in Blood Disorders and Cancer Louisville, Kentucky, United States, 40207 United States, Maryland Center for Cancer and Blood Disorders Bethesda, Maryland, United States, 20817 United States, Ohio Oncology Hematology Care Cincinnati, Ohio, United States, 45242 United States, Tennessee Chattanooga Oncology Hematology Associates Chattanooga, Tennessee, United States, 37404 Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 收起 <<
NCT00594230	-		Terminated(Per protocol, the r... 展开 >>esults of a planned interim analysis demonstrated insufficient efficacy and led to early termination of the study.) 收起 <<	-	-
NCT00632489	Breast Cancer	Phase 1	Completed	-	United States, Tennessee ... 展开 >> Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 收起 <<
NCT00550277	Renal Cell Carcinoma	Phase 2	Completed	-	United States, Florida ... 展开 >> Florida Cancer Specialists Fort Myers, Florida, United States, 33901 United States, Georgia Northeast Georgia Medical Center Gainesville, Georgia, United States, 30501 United States, Louisiana Baton Rouge General Medical Center Baton Rouge, Louisiana, United States, 70806 United States, Maryland Center for Cancer and Blood Disorders Bethesda, Maryland, United States, 20817 United States, Nebraska Methodist Cancer Center Omaha, Nebraska, United States, 68114 United States, New Jersey Hematology Oncology Associates of Northern NJ Morristown, New Jersey, United States, 07960 United States, Ohio Oncology Hematology Care Cincinnati, Ohio, United States, 45242 United States, Tennessee Chattanooga Oncology Hematology Associates Chattanooga, Tennessee, United States, 37404 Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 United States, Virginia Peninsula Cancer Institute Newport News, Virginia, United States, 23601 收起 <<
NCT00570284	Cancer	Phase 1	Completed	-	United States, California ... 展开 >> Novartis Investigative Site Los Angeles, California, United States United States, Connecticut Novartis Investigative Site Norwalk, Connecticut, United States United States, Maryland Novartis Investigative Site Rockville, Maryland, United States United States, Massachusetts Novartis Investigative Site Boston, Massachusetts, United States United States, New Hampshire Novartis Investigative Site Lebanon, New Hampshire, United States United States, New York Novartis Investigative Site New York, New York, United States United States, Wisconsin Novartis Investigative Site Madison, Wisconsin, United States Sweden Novartis Investigative Site Stokholm, Sweden Switzerland Novartis Investigative Site Zurich, Switzerland 收起 <<
NCT00550277	-		Completed	-	-
NCT00739414	Cancer Advanc... 展开 >>ed Solid Tumor 收起 <<	Phase 1	Completed	-	Japan ... 展开 >> Novartis Investigational Site Aichi prefecture, Japan Novartis Investigational Site Hokkaido, Japan Novartis Investigational Site Hyogo prefecture, Japan 收起 <<
NCT00848523	Recurrent Malignant Gliomas	Phase 2	Terminated(insufficient accrua... 展开 >>l) 收起 <<	-	United States, New York ... 展开 >> Long Island Brain Tumor Center at Neurological Surgery PC / Long Island Neuro-Oncology Associates Commack, New York, United States, 11725 Long Island Brain Tumor Center at Neurological Surgery PC / Long Island Neuro-Oncology Associates Great Neck, New York, United States, 11021 收起 <<
NCT01301807	Non-Secretory Plasma Cell Myel... 展开 >>oma Plasmacytosis Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma 收起 <<	Phase 1	Active, not recruiting	August 31, 2019	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01298934	Primary Myelofibrosis ... 展开 >> Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase Post-Essential Thrombocythemia Related Myelofibrosis 收起 <<	Phase 1 Phase 2	Unknown	July 2015	United States, New York ... 展开 >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 收起 <<
NCT00743288	Multiple Myeloma	Phase 1 Phase 2	Completed	-	United States, California ... 展开 >> Comprehensive Blood and Cancer Center Bakersfield, California, United States, 93309-0633 James R. Berenson MD, Incorporated West Hollywood, California, United States, 90069 United States, Colorado Rocky Mountain Cancer Centers - Denver Midtown Denver, Colorado, United States, 80218 United States, Maryland Center for Cancer and Blood Disorders Bethesda, Maryland, United States, 20817 收起 <<
NCT00997399	Advanced Solid Tumors	Phase 1	Completed	-	United States, Utah ... 展开 >> University of Utah / Huntsman Cancer Institute Salt Lake City, Utah, United States, 84103 Netherlands Novartis Investigative Site Leiden, Netherlands, 2300 RC Novartis Investigative Site Utrecht, Netherlands, 3584CX Switzerland Novartis Investigative Site St. Gallen, Switzerland, 9007 United Kingdom Novartis Investigative Site Merseyside, United Kingdom, L63 4JY 收起 <<
NCT00840346	Acute Myeloblastic Leukaemia	Phase 1 Phase 2	Completed	-	Spain ... 展开 >> Hospital Clinic y Provincial de Barcelona Barcelona, Spain Hospital Germans Trías i Pujol Barcelona, Spain Hospital Santa Creu y Sant Pau. Barcelona Barcelona, Spain Hospital 12 de Octubre. Madrid Madrid, Spain Hospital Clínico San Carlos. Madrid Madrid, Spain Hospital Ramón y Cajal. Madrid Madrid, Spain Hospital Morales Messeguer. Murcia Murcia, Spain Hospital Univ. La Fe de Valencia Valencia, Spain Hospital Lozano Blesa. Zaragoza Zaragoza, Spain 收起 <<
NCT01023308	Multiple Myeloma	Phase 3	Completed	-	-
NCT01613976	Myelodysplastic Syndromes (MDS... 展开 >>) Chronic Myelomonocytic Leukemia (CMML) Acute Myeloid Leukemia (AML) 收起 <<	Phase 1	Completed	-	Japan ... 展开 >> Novartis Investigative Site Nagoya-city, Aichi, Japan, 466-8650 Novartis Investigative Site Nagoya, Aichi, Japan, 460-0001 Novartis Investigative Site Kobe-city, Hyogo, Japan, 650-0017 Novartis Investigative Site Sendai-city, Miyagi, Japan, 980-8574 Novartis Investigative Site Chuo-ku, Tokyo, Japan, 104-0045 Novartis Investigative Site Kyoto, Japan, 602-8566 收起 <<
NCT01023308	-		Completed	-	-
NCT01433445	Idiopathic Myelofibrosis ... 展开 >> Post Essential Thrombocythemia Myelofibrosis Post Polycythemia-Vera Myelofibrosis 收起 <<	Phase 1	Active, not recruiting	December 31, 2018	France ... 展开 >> Novartis Investigative Site Paris, France, 75010 Novartis Investigative Site Villejuif Cedex, France, 94805 Germany Novartis Investigative Site Magdeburg, Germany, 39120 Novartis Investigative Site Mainz, Germany, 55131 Ireland Novartis Investigative Site Dublin, Ireland, DUBLIN 8 Novartis Investigative Site Galway, Ireland Italy Novartis Investigative Site Firenze, FI, Italy, 50134 Novartis Investigative Site Reggio Calabria, RC, Italy, 89124 Novartis Investigative Site Varese, VA, Italy, 21100 United Kingdom Novartis Investigative Site London, United Kingdom, SE1 9RT 收起 <<
NCT01013597	Thyroid Carcinoma	Phase 2	Completed	-	United States, Wisconsin ... 展开 >> St. Vincent Regional Cancer Center CCOP Green Bay, Wisconsin, United States, 54301 University of Wisconsin - Madison Madison, Wisconsin, United States, 53792 Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226 收起 <<
NCT00663832	Prostate Cancer	Phase 1	Completed	-	United States, Maryland ... 展开 >> Novartis Investigative Site Rockville, Maryland, United States, 20850 United States, Michigan Novartis Investigative Site Detroit, Michigan, United States, 48201 United States, Missouri Novartis Investigative Site St. Louis, Missouri, United States, 63110 United States, Nevada Novartis Investigative Site Las Vegas, Nevada, United States, 89135 United States, New York Novartis Investigative Site New York, New York, United States, 10021 United States, North Carolina Novartis Investigative Site Durham, North Carolina, United States, 27710 United States, Oregon Novartis Investigative Site Portland, Oregon, United States, 97239 Canada, British Columbia Novartis Investigative Site Vancouver, British Columbia, Canada, V5Z 1L8 Canada, Ontario Novartis Investigative Site Hamilton, Ontario, Canada, L8V 5C2 收起 <<
NCT00670553	Prostate Cancer ... 展开 >> Head & Neck Cancer Esophageal Cancer 收起 <<	Phase 1	Completed	-	Belgium ... 展开 >> Novartis Investigative Site Liege, Belgium 收起 <<
NCT00743288	-		Completed	-	-
NCT01651039	Multiple Myeloma	Phase 2	Completed	-	United States, New York ... 展开 >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 收起 <<
NCT01013597	-		Completed	-	-
NCT01136499	Soft Tissue Sarcoma	Phase 2	Completed	-	France ... 展开 >> Centre Léon Berard Lyon, France 收起 <<
NCT01549431	Multiple Myeloma	Phase 1	Active, not recruiting	December 2018	United States, California ... 展开 >> UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94115 United States, Georgia Emory University Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 收起 <<
NCT01523834	Diffuse Large B-cell Lymphoma	Phase 2	Completed	-	Italy ... 展开 >> Azienda Ospedaliera SS. Antonio e Biagio e C. Arrigo Alessandria, Italy, 15121 Istituto di Ematologia ed Oncologia Medica A. Seragnoli Policlinico S. Orsola Bologna, Italy, 40138 Spedali Civili Brescia, Italy Ematologia I, A.O.U. San Martino Genova, Italy, 16132 Ospedale Umberto I - DH Oncoematologico Nocera Inferiore, Italy Divisione di Ematologia Università Avogadro Novara, Italy AO Ospedali Riuniti Villa Sofia-Cervello Palermo, Italy, 90146 A.O. Città della Salute e della Scienza (Ematologia Univ) Torino, Italy A.O. Città della salute e della scienza (S.C. Ematologia) Torino, Italy AO Universitaria di Udine Udine, Italy 收起 <<
NCT01321346	Lymphoblastic Leukemia, Acute,... 展开 >> Childhood Myelogenous Leukemia, Acute, Childhood Hodgkin's Disease Non-Hodgkin's Lymphoma 收起 <<	Phase 1	Completed	-	-
NCT01651039	-		Completed	-	-
NCT00901147	Peripheral T-cell Lymphoma (No... 展开 >>t Otherwise Specified) Angioimmunoblastic T-cell Lymphoma Extranodal NK/T-cell Lymphoma Nasal Type Enteropathy- Type T-cell Lymphoma Hepatosplenic T-cell Lymphoma Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative) Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant 收起 <<	Phase 2	Completed	-	Korea, Republic of ... 展开 >> Samsung Medical Centre Seoul, Korea, Republic of, 135-710 Malaysia Subang Jaya Medical Centre Subang Jaya, Selangor, Malaysia, 47500 Hospital Universiti Kebangsaan Malaysia ( HUKM ) Kuala Lumpur, Malaysia, 56000 Singapore National Cancer Center Singapore, Singapore, 169608 Singapore General Hospital Singapore, Singapore, 169608 收起 <<
NCT01658241	Nodal Lymphoma ... 展开 >> Lymphoma With Cutaneous Involvement Lymphoma in Leukemic Phase Marrow Involvement With Lymphoma Multiple Myeloma 收起 <<	Phase 2	Active, not recruiting	July 2018	Australia, Victoria ... 展开 >> Peter MacCallum Cancer Centre Melbourne, Victoria, Australia, 3002 收起 <<
NCT00925132	-		Terminated(Change in the numbe... 展开 >>r of approved drugs for metastatic melanoma) 收起 <<	-	-
NCT02722941	Multiple Myeloma	Phase 2	Recruiting	June 2021	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Recruiting Tampa, Florida, United States, 33612 Contact: Caitlyn Ward 813-745-1344 caitlyn.ward@moffitt.org Contact: Taiga Nishihori 813-745-8156 taiga.nishihori@moffitt.org Principal Investigator: Taiga Nishihori, M.D. Sub-Investigator: Melissa Alsina, M.D. Sub-Investigator: Claudio Anasetti, M.D. Sub-Investigator: Ernesto Ayala, M.D. Sub-Investigator: Rachid Baz, M.D. Sub-Investigator: Brian Betts, M.D. Sub-Investigator: Hugo Fernandez, M.D. Sub-Investigator: Jingsong Zhang, M.D., Ph.D. Sub-Investigator: Mohamed Kharfan-Dabaja, M.D. Sub-Investigator: Farhad Khimani, M.D. Sub-Investigator: Frederick Locke, M.D. Sub-Investigator: Asmita Mishra, M.D. Sub-Investigator: Jose Ochoa-Bayona, M.D. Sub-Investigator: Lia Perez, M.D. Sub-Investigator: Joseph Pidala, M.D., Ph.D. Sub-Investigator: Kenneth Shain, M.D., Ph.D. 收起 <<
NCT00742027	Classical Hodgkin's Lymphoma (... 展开 >>i.e. Nodular Sclerosing, Mixed-cellularity, Lymphocyte-rich, Lymphocyte-depleted) 收起 <<	Phase 2	Completed	-	-
NCT00925132	Metastatic Melanoma	Phase 1 Phase 2	Terminated(Change in the numbe... 展开 >>r of approved drugs for metastatic melanoma) 收起 <<	-	United States, Iowa ... 展开 >> University of Iowa Hospitals and Clinics Iowa City, Iowa, United States, 52242 收起 <<
NCT03632317	Glioma Diffus... 展开 >>e Intrinsic Pontine Glioma 收起 <<	Phase 2	Recruiting	September 2025	United States, Michigan ... 展开 >> University of Michigan Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Carl Koschmann, M.D. 734-615-2736 ckoschma@umich.edu Principal Investigator: Carl Koschmann, MD 收起 <<
NCT01460940	Adult Lymphocyte Depletion Hod... 展开 >>gkin Lymphoma Adult Lymphocyte Predominant Hodgkin Lymphoma Adult Mixed Cellularity Hodgkin Lymphoma Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma Adult Nodular Sclerosis Hodgkin Lymphoma Recurrent Adult Hodgkin Lymphoma 收起 <<	Phase 2	Completed	-	United States, Missouri ... 展开 >> Washington University Saint Louis, Missouri, United States, 63110 United States, Ohio The Ohio State University Medical Center Columbus, Ohio, United States, 43210 收起 <<
NCT01282476	-		Terminated(slow accrual)	-	-
NCT01460940	-		Completed	-	-
NCT01065467	Melanoma Mali... 展开 >>gnant Melanoma 收起 <<	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 收起 <<
NCT01282476	Diffuse Large B Cell Lymphoma	Phase 2	Terminated(slow accrual)	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02214 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 收起 <<
NCT00985946	Neuroendocrine Tumors	Phase 2	Terminated(Study did not meet ... 展开 >>statistical requirements to continue.) 收起 <<	-	United States, Wisconsin ... 展开 >> University of Wisconsin, Madison Madison, Wisconsin, United States, 53792 收起 <<
NCT00985946	-		Terminated(Study did not meet ... 展开 >>statistical requirements to continue.) 收起 <<	-	-
NCT00967044	-		Completed	-	-
NCT01504776	Mantle Cell Lymphoma	Phase 1	Completed	-	United States, Georgia ... 展开 >> Georgia Regents University Augusta, Georgia, United States, 30912 收起 <<
NCT01693601	Myelofibrosis	Phase 1 Phase 2	Active, not recruiting	February 2019	United States, New York ... 展开 >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 收起 <<
NCT01336842	Solid Tumors ... 展开 >>Non-Small Cell Lung Cancer (NSCLC) 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> University of California Davis Cancer Center Sacramento, California, United States, 95817 United States, Michigan Henry Ford Health System Detroit, Michigan, United States, 48202 收起 <<
NCT00931762	Primary Myelofibrosis ... 展开 >> Post-Polycythemia Vera Post-Essential Thrombocytopenia 收起 <<	Phase 2	Completed	-	United States, Arizona ... 展开 >> Mayo Clinic - Scottsdale Scottsdale, Arizona, United States, 85259 United States, California City of Hope National Medical Center Duate, California, United States, 91010 Stanford Comprehensive Cancer Center Stanford, California, United States, 94305 United States, Georgia Medical College of Georgia Augusta, Georgia, United States, 30912 United States, Illinois Northwestern University Feinberg School of Medicine Chicago, Illinois, United States, 60611 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109 United States, Minnesota Mayo Clinic - Rochester Rochester, Minnesota, United States, 55905 United States, New York New York Prebyterian Hospital - Weill Cornell Medical College New York, New York, United States, 10021 收起 <<
NCT01451268	Myelodysplastic Syndrome ... 展开 >> Acute Myeloid Leukemia 收起 <<	Phase 1 Phase 2	Active, not recruiting	April 2018	Germany ... 展开 >> University Hospital Düsseldorf Düsseldorf, Germany, 40225 University Hospital Essen Essen, Germany, 45147 University Hospital Frankfurt Frankfurt am Main, Germany, 60590 University Hospital Hamburg-Eppendorf Hamburg, Germany, 20246 University Hospital Mainz Mainz, Germany, 55131 University Hospital Marburg Marburg, Germany, 35043 收起 <<
NCT02568943	-		-	-	-
NCT01115036	Recurrent Glioblastoma	Phase 2	Withdrawn(No subjects were enr... 展开 >>olled on this study, so study was closed and IND withdrawn.) 收起 <<	April 2012	United States, North Carolina ... 展开 >> Duke University Medical Center Durham, North Carolina, United States, 27710 收起 <<
NCT00967044	Lymphoma	Phase 1 Phase 2	Completed	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01680094	HIV Infection	Phase 1 Phase 2	Completed	-	Denmark ... 展开 >> Department of Infectious Diseases, Aarhus University Hospital Aarhus, Denmark, 8200 收起 <<
NCT02032810	Melanoma Skin... 展开 >> Cancer 收起 <<	Phase 1	Active, not recruiting	December 2019	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 收起 <<
NCT01242774	Acute Myeloid Leukemia (AML)	Phase 1	Completed	-	United States, California ... 展开 >> Stanford University Medical Center Stanford U Stanford, California, United States, 94304 United States, Massachusetts Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr Boston, Massachusetts, United States, 02115 United States, Ohio Ohio State Comprehensive Cancer Center/James Cancer Hospital Dept.ofJamesCancerHospital Columbus, Ohio, United States, 43210 United States, South Carolina Medical University of South Carolina -Hollings Cancer Center MUSC/HCC (2) Charleston, South Carolina, United States, 29425 United States, Tennessee Vanderbilt University Medical Center, Clinical Trials Center Vanderbilt 3 Nashville, Tennessee, United States, 37212 Germany Novartis Investigative Site Dresden, Germany, 01307 Novartis Investigative Site Hannover, Germany, 30625 Novartis Investigative Site Ulm, Germany, 89081 Spain Novartis Investigative Site Salamanca, Castilla y Leon, Spain, 37007 Novartis Investigative Site Barcelona, Spain, 08025 收起 <<
NCT02717455	Glioma	Phase 1	Recruiting	October 1, 2019	United States, California ... 展开 >> Children's Hospital Los Angeles Recruiting Los Angeles, California, United States, 90026 Contact: Girish Dhall, MD 323-361-4629 gdhall@chla.usc.edu Contact: Kelley Haley, BSN,RN,CCRP 323-361-2480 khaley@chla.usc.edu Principal Investigator: Girish Dhall, MD Stanford University and Lucile Packard Children's Hospital Recruiting Palo Alto, California, United States, 94304 Contact: Paul Graham Fisher, MD 650-721-5889 pfisher@stanford.edu Contact: Leah White 650-725-4708 lwhite15@stanford.edu Principal Investigator: Paul Graham Fisher, MD United States, District of Columbia Children's National Medical Center Recruiting Washington, D.C., District of Columbia, United States, 20010 Contact: Roger Packer, MD 202-884-2120 rpacker@cnmc.org Contact: Chad Stephans 202-476-4481 CStephan@childrensnational.org Principal Investigator: Roger Packer, MD United States, Illinois Ann & Robert H. Lurie Children's Hospital of Chicago Recruiting Chicago, Illinois, United States, 60611 Contact: Stewart Goldman, MD 312-227-4844 sgoldman@luriechildrens.org Contact: Emily Golbeck 312-227-4858 egolbeck@luriechildrens.org Principal Investigator: Stewart Goldman, MD United States, Maryland National Cancer Institute Recruiting Bethesda, Maryland, United States, 20892 Contact: Kathy Warren, MD 301-435-4683 warrenk@mail.nih.gov Contact: Sonja Crandon, RN,BSN,PMP 301-496-8009 Sonja.crandon@nih.gov Principal Investigator: Kathy Warren, MD United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Ira Dunkel, MD 212-639-2153 dunkeli@mskcc.org Contact: Ryan Turner 646-888-5723 turnerr@mskcc.org Principal Investigator: Ira Dunkel, MD United States, Ohio Cincinnati Children's Hospital Medical Center Recruiting Cincinnati, Ohio, United States, 45229 Contact: Maryam Fouladi, MD 513-803-0721 maryam.fouladi@cchmc.org Contact: CCHMC Cancer Line 513-636-2799 Cancer@cchmc.org Principal Investigator: Maryam Fouladi, MD United States, Pennsylvania Children's Hospital of Pittsburgh Recruiting Pittsburgh, Pennsylvania, United States, 15224 Contact: Arthur 'Kim' Ritchey, MD 412-692-6794 ritcheyak@upmc.edu Contact: Sharon DiBridge 412-692-7070 sharon.dibridge@chp.edu Principal Investigator: Arthur 'Kim' Ritchey, MD United States, Tennessee St. Jude Children's Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Alberto Broniscer, MD 901-595-4925 alberto.broniscer@stjude.org Contact: Dillon Robinson 901-595-5922 Dillon.Robinson@stjude.org Principal Investigator: Alberto Broniscer, MD United States, Texas Baylor College of Medicine Recruiting Houston, Texas, United States, 77030 Contact: Patricia Baxter, MD 832-824-4681 pabaxter@txch.org Contact: Susan Burlingame, CCRP 832-824-1532 sxburlin@txch.org Principal Investigator: Patricia Baxter, MD 收起 <<
NCT01802879	Hematologic Neoplasms	Phase 2	Active, not recruiting	November 22, 2018	United States, California ... 展开 >> City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(1) Duarte, California, United States, 91010-3000 United States, Georgia Georgia Regents University SC-2 Augusta, Georgia, United States, 30912 United States, Massachusetts Dana Farber Cancer Institute Reg. Ped Boston, Massachusetts, United States, 02215 United States, Utah University of Utah / Huntsman Cancer Institute SC-2 Salt Lake City, Utah, United States, 84103 Israel Novartis Investigative Site Jerusalem, Israel, 91120 Netherlands Novartis Investigative Site Leiden, Netherlands, 2300 RC Spain Novartis Investigative Site Salamanca, Castilla Y Leon, Spain, 37007 收起 <<
NCT01496118	Multiple Myeloma	Phase 1 Phase 2	Active, not recruiting	December 2019	United States, Colorado ... 展开 >> Colorado Blood Cancer Institute Denver, Colorado, United States, 80218 United States, Florida Florida Cancer Specialists South Fort Myers, Florida, United States, 33916 Woodlands Medical Specialists Pensacola, Florida, United States, 32503 Florida Cancer Specialists North Saint Petersburg, Florida, United States, 33705 United States, Indiana Providence Medical Group Terre Haute, Indiana, United States, 47802 RHHP/Hope Cancer Center Terre Haute, Indiana, United States, 47802 United States, Missouri Research Medical Center Kansas City, Missouri, United States, 64132 United States, New Jersey Hematology-Oncology Associates - Northern NJ Morristown, New Jersey, United States, 07962 United States, Ohio Oncology Hematology Care, Inc. Cincinnati, Ohio, United States, 45242 United States, Oklahoma Cancer Centers of Southwest Oklahoma Lawton, Oklahoma, United States, 73505 United States, Tennessee Tennessee Oncology-Chattanooga Chattanooga, Tennessee, United States, 37404 Tennessee Oncology Nashville, Tennessee, United States, 37205 United States, Texas The Center for Cancer and Blood Disorders Fort Worth, Texas, United States, 76104 收起 <<
NCT01245179	Sickle Cell Disease	Phase 1	Active, not recruiting	July 2023	United States, Georgia ... 展开 >> Augusta University Augusta, Georgia, United States, 30912 收起 <<

帕比司他 /Panobinostat {[allProObj[0].p_purity_real_show]}

Panobinostat 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Panobinostat 质控信息

Panobinostat 生物活性

Panobinostat 细胞研究

Panobinostat 动物研究

Panobinostat 临床研究

Panobinostat 参考文献

Panobinostat 实验方案

Panobinostat 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

帕比司他 /Panobinostat {[allProObj[0].p_purity_real_show]}

Panobinostat 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Panobinostat 质控信息

Panobinostat 生物活性

Panobinostat 细胞研究

Panobinostat 动物研究

Panobinostat 临床研究

Panobinostat 参考文献

Panobinostat 实验方案

Panobinostat 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Panobinostat 纯度/质量文件产品仅供科研